United States Army Medical Research Institute of Infectious Diseases

Sarepta Therapeutics Announces Research Agreement with U.S. Department of Defense to Evaluate Multiple Constructs From its Proprietary RNA Platform as Treatments for COVID-19

Retrieved on: 
Tuesday, April 28, 2020
Anthrax attacks, Fort Detrick, Severe acute respiratory syndrome-related coronavirus, United States Army Medical Research Institute of Infectious Diseases, Virus

USAMRIID will evaluate the constructs on characterized wild-type SARS-CoV-2 viruses for their potential to inhibit viral infection.

Key Points: 
  • USAMRIID will evaluate the constructs on characterized wild-type SARS-CoV-2 viruses for their potential to inhibit viral infection.
  • Based on the results, Sarepta and USAMRIID will consider collaborative funding proposals to advance the development of treatments for COVID-19.
  • Indeed, we have already built and manufactured therapeutic PPMO constructs and are providing them now to USAMRIID for testing and evaluation.
  • Sarepta does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof.

2019 Half-year consolidated results: Deinove’s progress coming to fruition

Retrieved on: 
Thursday, September 26, 2019
RTT, Drugs, Fluoroquinolone antibiotics, Otologicals, Piperazines, Medicine, Health, Anthrax attacks, United States Army Medical Research Institute of Infectious Diseases, Ciprofloxacin, Anthrax, American Society for Microbiology

Investigation centers have been selected and the enrolement of the first patient is expected in the coming weeks.

Key Points: 
  • Investigation centers have been selected and the enrolement of the first patient is expected in the coming weeks.
  • DNV3681 has demonstrated a higher in vitro efficacy than Ciprofloxacin, the reference product in the event of exposure to anthrax bacteria.
  • These data were presented at the American Society of Microbiology Congress, ASM Microbe 2019, by Major Steven Zumbrun, PhD in Microbiology at USAMRIID.
  • Dow has selected one of the extracts of interest from DEINOVE's bacterial collection based on promising in vitro results.